Cutaneous Oncology News

This month, Healio announced the launch of its latest podcast, Oncology Overdrive.

Black patients with earlier-stage melanoma were more likely than their non-Hispanic white counterparts to experience delayed time from diagnosis to definitive surgery, according to a study.

Lymph node status is a predictor of survival in patients with vulvar melanoma and vaginal melanoma, according to a study published in American Journal of Clinical Dermatology.

Nivolumab administered 4 weeks before surgery induced pathologic complete responses and radiographic tumor regressions in about half of a cohort of patients with Merkel cell carcinoma, according to results of the phase 1/phase 2 CheckMate 358 study published in Journal of Clinical Oncology.

The FDA has approved Nevisense 3.0, an artificial intelligence system for early melanoma detection, SciBase announced in a press release.

The FDA approved an additional recommended dosage of pembrolizumab, authorizing its use at 400 mg every 6 weeks.

Researchers from the Department of Epidemiology at University of California, Irvine, found that age is a factor in the interaction between sex and ultraviolet index in melanoma.

An alternative pembrolizumab dosing regimen of 400 mg every 6 weeks appeared safe and effective for patients with metastatic melanoma, according to first clinical outcomes data from KEYNOTE-555 cohort B presented at the virtual American Association for Cancer Research Annual Meeting.

Mohs micrographic surgery was superior to wide local excision as measured by local recurrence rates in a cohort of patients with T2a squamous cell carcinoma, according to a study.

Continuous dosing of dabrafenib and trametinib conferred superior PFS compared with intermittent dosing of the targeted agents among patients with BRAF V600E- and V600K-mutant melanoma, according to results of a randomized phase 2 study presented at the virtual American Association for Cancer Research Annual Meeting.